Economy/Home · Economy

Peptron Rises 800 Won for Second Straight Day of Gains... With Fed Freezing Rates, Can KOSPI Hold 6,000 and KOSDAQ Sustain Its Rebound?

Peptron continued its upward momentum in early trading on the 29th, marking its second consecutive day of gains. With the U.S. Federal Reserve (Fed) having frozen its benchmark interest rate, attention is focused on whether the upward trend in the KOSPI and KOSDAQ can continue in the domestic stock

Wooil Shim
Staff Reporter
11 min read
Peptron Rises 800 Won for Second Straight Day of Gains... With Fed Freezing Rates, Can KOSPI Hold 6,000 and KOSDAQ Sustain Its Rebound?
CBC News

Peptron continued its upward momentum in early trading on the 29th, marking its second consecutive day of gains. With the U.S. Federal Reserve (Fed) having frozen its benchmark interest rate, attention is focused on whether the upward trend in the KOSPI and KOSDAQ can continue in the domestic stock market.

■ Peptron Up for Second Straight Day... Watch on Whether It Re-enters the 100,000-Won Level

On the morning of the 29th, Peptron (087010) was trading at 98,000 won, up 800 won from the previous trading day, a gain of 0.82%. Following its rise the previous day, Peptron is recording its second consecutive day of gains, and within this trend, whether the stock price can re-enter the 100,000-won range has emerged as a point of interest.

Peptron is a biotech company pursuing the development of long-acting medicines based on drug delivery technology. This technology, designed to release drugs over a set period in the body, can be used to reduce dosing frequency and improve treatment convenience. In particular, as interest in obesity treatments and metabolic disease drugs continues in the global pharmaceutical and biotech industries, the commercial feasibility of long-acting drug delivery technology has become an important focus of attention.

However, for market expectations regarding the technology to translate into actual revenue and profit, it must be supported by research and development results, clinical trials, technology transfer agreements, and commercialization processes. Whether technology transfer agreements are concluded, the scale of such contracts, achievements at each development stage, and commercialization potential are key factors in assessing corporate value, meaning the competitiveness of the technology and actual business performance should be evaluated separately. Biotech companies can see increased stock price volatility depending on R&D announcements or clinical trial results, and in situations where market expectations have risen, results that differ from forecasts could quickly shift investor sentiment.

■ Fed Freezes Benchmark Rate at 3.75–4.00% Annually... A Variable for Biotech Funding Conditions

U.S. monetary policy is also a variable that can affect domestic biotech investor sentiment. On the 28th local time, the Fed concluded its Federal Open Market Committee (FOMC) meeting and froze the benchmark rate at 3.75–4.00% annually. While the Fed assessed that the U.S. economy is maintaining solid growth, it emphasized that inflation remains at a high level. With this decision, the U.S. benchmark rate stays at its current level, but uncertainty remains over the future direction of monetary policy.

The biotech industry is characterized by long-term capital investment in R&D. In particular, new drug developers require substantial funding throughout clinical trials, technology development, and commercialization, so they can be affected by the interest rate environment and changes in investors' risk appetite. If upward pressure on interest rates eases, it could act as a positive factor for growth companies' financing conditions and valuation. Conversely, if high interest rates persist for a long time, R&D companies may face increased fundraising burdens. However, it is difficult to conclude that Peptron's rise on this day is a direct result of the U.S. rate freeze.

■ KOSPI Recovers 6,000 Level, KOSDAQ Up 3.69%... Sustainability Is Key

In the domestic market, the recent upward trends of the KOSPI and KOSDAQ are also drawing attention. On the 28th, the KOSPI closed at 6,012.44, up 374.10 points from the previous trading day, a gain of 6.63%, recovering the 6,000 level. The KOSDAQ also closed at 771.28, up 27.45 points, a rise of 3.69%.

While both markets rose together, showing improving investor sentiment in the domestic stock market, it remains to be seen whether this trend will continue on the 29th. In particular, in the KOSDAQ market, the stock prices of biotech and technology growth companies can react sensitively not only to individual companies' R&D results but also to overall market liquidity and changes in investor sentiment. Peptron is also maintaining its stock price trend within this market environment.

■ Future Checkpoints... Commercialization Progress, Supply-Demand Changes, U.S. Financial Markets

In the short term, whether buying interest continues, trading volume changes, and the overall KOSDAQ market trend are expected to be key variables for Peptron's stock price. How domestic financial markets move following the Fed's rate freeze also needs to be watched. In particular, whether the KOSPI can maintain its upward momentum after recovering the 6,000 level, and whether the KOSDAQ can extend its previous day's rebound, could influence investor sentiment.

Long-acting medicine technology is drawing attention in the global pharmaceutical industry as a field that can improve treatment convenience and drug delivery efficiency. Looking ahead at Peptron's stock price movement, the commercialization progress of this technology, the investment environment of the global pharmaceutical and biotech industries, and supply-demand changes in the domestic stock market are expected to draw attention together.

[This article is intended to provide information for investment reference and does not recommend buying or selling any specific stock. Conditions may vary depending on market circumstances. Investment decisions and any resulting responsibility lie with the investor. AI provided partial assistance.]

Wooil Shim
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.